Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic

Alzheimer's and Dementia

Volumn 13, Issue 1, 2017, Pages 45-58

  O'Bryant, Sid E ^a   Mielke, Michelle M ^b   Rissman, Robert A ^c   Lista, Simone ^d   Vanderstichele, Hugo ^e   Zetterberg, Henrik ^f,g   Lewczuk, Piotr ^h,i   Posner, Holly ^j   Hall, James ^a   Johnson, Leigh ^a   Fong, Yiu Lian ^k   Luthman, Johan ^l   Jeromin, Andreas ^m   Batrla Utermann, Richard ⁿ   Villarreal, Alcibiades ^o   Britton, Gabrielle ^o   Snyder, Peter J ^p   Henriksen, Kim ^q   Grammas, Paula ^r   Gupta, Veer ^s   Martins, Ralph ^s   Hampel, Harald ^d   more..

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SORBONNE UNIVERSITÉ   (France)

^e ADX NEUROSCIENCES   (Belgium)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

ⁱ MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^j PFIZER INC   (United States)

^k JOHNSON AND JOHNSON   (United States)

^l EISAI INC   (United States)

^m QUANTERIX CORPORATION   (United States)

ⁿ Roche Diagnostics Ltd   (Switzerland)

^o INSTITUTO DE INVESTIGACIONES CIENTÍFICAS Y SERVICIOS DE ALTA TECNOLOGÍA   (Panama)

^p BROWN UNIVERSITY   (United States)

^q NORDIC BIOSCIENCE A S   (Denmark)

^r UNIVERSITY OF RHODE ISLAND   (United States)

^s EDITH COWAN UNIVERSITY   (Australia)

more..

Author keywords

Alzheimer's disease; Biomarker; Blood; Cerebrospinal fluid; Context of use; Diagnosis; Imaging

Indexed keywords

AMYLOID; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; BLOOD; FOOD AND DRUG ADMINISTRATION; HOSPITAL; HUMAN; NONHUMAN; PHASE 4 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; RISK FACTOR; SHORT SURVEY; VALIDATION STUDY; COOPERATION; FEMALE; MALE; REPRODUCIBILITY;

ALZHEIMER DISEASE; BIOMARKERS; COOPERATIVE BEHAVIOR; FEMALE; HUMANS; MALE; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; REPRODUCIBILITY OF RESULTS;

EID: 85009063579     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2016.09.014     Document Type: Short Survey

References (68)

1. [1] Snyder, H.M., Carrillo, M.C., Grodstein, F., Henriksen, K., Jeromin, A., Lovestone, S., et al. Developing novel blood-based biomarkers for Alzheimer's disease. Alzheimers Dement 10 (2014), 109–114.
2. [2] Henriksen, K., O'Bryant, S.E., Hampel, H., Trojanowski, J.Q., Montine, T.J., Jeromin, A., et al. The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement 10 (2014), 115–131.
3. [3] O'Bryant, S.E., Introduction to special issue on advances in blood-based biomarkers of Alzheimer's disease. Alzheimers Dement (Amst) 3 (2016), 110–112.
4. [4] Lista, S., Faltraco, F., Prvulovic, D., Hampel, H., Blood and plasma-based proteomic biomarker research in Alzheimer's disease. Prog Neurobiol 101–102 (2013), 1–17.
5. [5] O'Bryant, S.E., Edwards, M., Johnson, L.A., Hall, J.A., Villarreal, A.E., Britton, G.B., et al. A blood screening test for Alzheimer's disease. Alzheimers Dement (Amst) 3 (2016), 83–90.
6. [6] Schneider, P., Hampel, H., Buerger, K., Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. CNS Neurosci Ther 15 (2009), 358–374.
7. [7] Laske, C., Sohrabi, H.R., Frost, S.M., Lopez-De-Ipina, Garrard, P., Buscema, M., et al. Innovative diagnostic tools for early detection of Alzheimer's disease. Alzheimers Dement 11 (2015), 561–578.
8. [8] O'Bryant, S.E., Gupta, V., Henriksen, K., Edwards, M., Jeromin, A., Lista, S., et al. Guidelines for the standardization fo preanalytic variables for blood-based biomarker studies in Alzheimer's disease. Alzheimers Dement 11 (2015), 549–560.
9. [9] O'Bryant, S.E., Lista, S., Rissman, R.A., Edwards, M., Zhang, F., Hall, J., et al. Comparing biological markers of Alzheimer's disease across blood fraction and platforms: comparing apples to oranges. Alzheimers Dement (Amst) 3 (2016), 27–34.
10. [10] Vanderstichele, H.M., Shaw, L., Vandijck, M., Jeromin, A., Zetterberg, H., Blennow, K., et al. Alzheimer disease biomarker testing in cerebrospinal fluid: a method to harmonize assay platforms in the absence of an absolute reference standard. Clin Chem 59 (2013), 710–712.
11. [11] Andreasson, U., Blennow, K., Zetterberg, H., Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. Alzheimers Dement (Amst) 3 (2016), 98–102.
12. [12] Bowsher, R.R., Nowatzke, W., Sailstad, J.M., Khan, M.U., Application of commercial research-grade biomarker assays in drug development: is it time to create ‘pharmaceutical-grade’ kits?. Bioanalysis 4 (2012), 2427–2430.
13. [13] Bowsher, R.R., Sailstad, J.M., Insights in the application of research-grade diagnostic kits for biomarker assessments in support of clinical drug development: bioanalysis of circulating concentrations of soluble receptor activator of nuclear factor κB ligand. J Pharm Biomed Anal 48 (2008), 1282–1289.
14. [14] Blennow, K., de Meyer, G., Hansson, O., Minthon, L., Wallin, A., Zetterberg, H., et al. Evolution of Aβ42 and Aβ40 levels and Aβ42/Aβ40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment. J Nutr Health Aging 13 (2009), 205–208.
15. 42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 31 (2010), 357–367.
16. [16] Chouraki, V., Beiser, A., Younkin, L., Preis, S.R., Weinstein, G., Hansson, O., et al. Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study. Alzheimers Dement 11 (2015), 249–257.e1.
17. [17] Mapstone, M., Cheema, A.K., Fiandaca, M.S., Zhong, X., Mhyre, T.R., Macarthur, L.H., et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 20 (2014), 415–418.
18. [18] Casanova, R., Varma, S., Simpson, B., Kim, M., An, Y., Saldana, S., et al. Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals. Alzheimers Dement 12 (2016), 815–822.
19. [19] Li, D., Misialek, J., Boerwinkle, E., Gottesman, R.F., Sharrett, A.R., Mosley, T.H., et al. Plasma phospholipids and prevalence of mild cognitive impairment/dementia in the ARIC Neurocognitive Study (ARIC-NCS). Alzheimers Dement (Amst) 3 (2016), 73–82.
20. [20] Hye, A., Riddoch-Contreras, J., Baird, A.L., Ashton, N.J., Bazenet, C., Leung, R., et al. Plasma proteins predict conversion to dementia from prodromal disease. Alzheimers Dement 10 (2014), 799–807.e2.
21. [21] Malm, T., Loppi, S., Kanninen, K.M., Exosomes in Alzheimer's disease. Neurochem Int 97 (2016), 193–199.
22. [22] Kanninen, K.M., Bister, N., Koistinaho, J., Malm, T., Exosomes as new diagnostic tools in CNS diseases. Biochim Biophys Acta 1862 (2016), 403–410.
23. [23] Stern, R.A., Tripodis, Y., Baugh, C.M., Fritts, N.G., Martin, B.M., Chaisson, C., et al. Preliminary study of plasma exosomal tau as a potential biomarker for chronic traumatic encephalopathy. J Alzheimers Dis 51 (2016), 1099–1109.
24. [24] Winston, C.N., Goetzl, E.J., Akers, J.C., Carter, B.S., Rockenstein, E.M., Galasko, D., et al. Prediction of conversion from mild cognitive impairment to dementia with neuronally-derived blood exosome protein profile. Alzheimers Dement (Amst) 3 (2016), 63–72.
25. [25] Weinstein, G., Beiser, A.S., Preis, S.R., Courchesne, P., Chouraki, V., Levy, D., et al. Plasma clusterin levels and risk of demenita, Alzheimer's disease and stroke. Alzheimers Dement (Amst) 3 (2016), 103–109.
26. [26] Chang, K.A., Shin, K.Y., Nam, E., Lee, Y.B., Moon, C., Suh, Y.H., Lee, S.H., Plasma soluble neuregulin-1 as a diagnostic biomarker for Alzheimer's disease. Neurochem Int 97 (2016), 1–7.
27. [27] Blasko, I., Kemmler, G., Jungwirth, S., Wichart, I., Krampla, W., Weissgram, S., et al. Plasma amyloid beta-42 independently predicts both late-onset depression and Alzheimer disease. Am J Geriatr Psychiatry 18 (2010), 973–982.
28. [28] Olsson, B., Lautner, R., Andreasson, U., Ohrfelt, A., Portelius, E., Bjerke, M., et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol 15 (2016), 673–684.
29. [29] Dage, J.L., Wennberg, A.M., Airey, D.C., Hagen, C.E., Knopman, D.S., Machulda, M.M., et al. Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort. Alzheimers Dement, 2016, 10.1016/j.jalz.2016.06.001.
30. [30] Zetterberg, H., Wilson, D., Andreasson, U., Minthon, L., Blennow, K., Randall, J., Hansson, O., et al. Plasma tau levels in Alzheimer's disease. Alzheimers Res Ther, 5, 2013, 9.
31. [31] Gisslen, M., Price, R.W., Andreasson, U., Norgren, N., Nilsson, S., Hagberg, L., et al. Plasma concentration of the neurofilament light protein (NFL) as a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine 3 (2016), 135–140.
32. [32] Bacioglu, M., Maia, L.F., Preische, O., Schelle, J., Apel, A., Kaeser, S.A., et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 91 (2016), 494–496.
33. [33] Gupta, V.B., Doecke, J.D., Hone, E., Pedrini, S., Laws, S.M., Thambissetty, M., et al. Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging. Alzheimers Dement (Amst) 3 (2016), 18–26.
34. [34] Nagele, E., Han, M., DeMarshall, C., Belinka, B., Nagele, R., et al. Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera. PLoS One, 6, 2011, e23112.
35. [35] DeMarshall, C.A., Han, M., Nagele, E.P., Sarkar, A., Acharya, N.K., Godsey, et al. Potential utility of autoantibodies as blood-based biomarkers for early detection and diagnosis of Parkinson's disease. Immunol Lett 168 (2015), 80–88.
36. [36] DeMarshall, C.A., Nagele, E.P., Sarkar, A., Acharya, N.K., Godsey, G., Goldwaser, E.L., et al. Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers. Alzheimers Dement (Amst) 3 (2016), 51–62.
37. [37] Savica, R., Murray, M.E., Persson, X.M., Kantarci, K., Parisi, J.E., Dickson, D.W., et al. Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology. Alzheimers Dement (Amst) 3 (2016), 43–50.
38. [38] O'Bryant, S.E., Xiao, G., Zhang, F., Edwards, M., German, D.C., Yin, X., et al. Validation of a serum screen for Alzheimer's disease across assay platforms, species, and tissues. J Alzheimers Dis 42 (2014), 1325–1335.
39. [39] Gold, L.S., Klein, G., Carr, L., Kessler, L., Sullivan, S.D., et al. The emergence of diagnostic imaging technologies in breast cancer: discovery, regulatory approval, reimbursement, and adoption in clinical guidelines. Cancer Imaging 12 (2012), 13–24.
40. [40] Westwood, S., Leoni, E., Hye, A., Lynham, S., Khondoker, M.R., Ashton, N.J., et al. Blood-based biomarker candidates of cerebral amyloid using PiB PET in non-demented elderly. J Alzheimers Dis 52 (2016), 561–572.
41. [41] Tzen, K.Y., Yang, S.Y., Chen, T.F., Cheng, T.W., Horng, H.E., Wen, H.P., et al. Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease. ACS Chem Neurosci 5 (2014), 830–836.
42. [42] Kaneko, N., Nakamura, A., Washimi, Y., Kato, T., Sakurai, T., Arahata, Y., et al. Novel plasma biomarker surrogating cerebral amyloid deposition. Proc Jpn Acad Ser B Phys Biol Sci 90 (2014), 353–364.
43. [43] Burnham, S.C., Faux, N.G., Wilson, W., Laws, S.M., Aimes, D., Bedo, J., et al. A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: results from the AIBL study. Mol Psychiatry 19 (2014), 519–526.
44. [44] Swaminathan, S., Risacher, S.L., Yoder, K.K., West, J.D., Shen, L., Kim, S., et al. Association of plasma and cortical amyloid beta is modulated by APOE ε4 status. Alzheimers Dement 10 (2014), e9–e18.
45. [45] Van Gool, S.W., De Meyer, G., Van De Voorde, A., Vanmechelen, E., Vanderstichele, H., et al. Neurotoxicity marker profiles in the CSF are not age-dependent but show variation in children treated for acute lymphoblastic leukemia. Neurotoxicology 25 (2004), 471–480.
46. [46] Van Gool, S.W., Van Kerschaver, E., Brock, P., Pottel, H., Hulstaert, F., Vanmechelen, E., et al. Disease- and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies. Leukemia 14 (2000), 2076–2084.
47. [47] Serban, M.A., Translational biomaterials—the journey from the bench to the market—think ‘product’. Curr Opin Biotechnol 40 (2016), 31–34.
48. [48] Tralau-Stewart, C.J., Wyatt, C.A., Kleyn, D.E., Ayad, A., et al. Drug discovery: new models for industry–academic partnerships. Drug Discov Today 14 (2009), 95–101.
49. [49] Ioannidis, J.P., Why most published research findings are false. PLoS Med, 2, 2005, e124.
50. [50] Collins, F.S., Tabak, L.A., NIH plans to enhance reproducibility. Nature 505 (2014), 612–613.
51. [51] Trouble at the lab, in The Economist. 2013.
52. [52] Prinz, F., Schlange, T., Asadullah, K., Believe it or not: how much can we rely on published data on potential drug targets?. Nat Rev Drug Discov 10 (2011), 712–713.
53. [53] Regelado, A., Merk wants its money back if university research is wrong. 2016, MIT Technology Review.
54. [54] Kiddle, S.J., Sattlecker, M., Proitsi, P., Simmons, A., Westman, E., Bazenet, C., et al. Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study. J Alzheimers Dis 38 (2014), 515–531.
55. [55] Soares, H.D., Chen, Y., Sabbagh, M., Rohrer, A., Schrijvers, E., Breteler, M., Identifying early markers of alzheimer's disease using quantitative multiplex proteomic immunoassay panels. Ann N Y Acad Sci 1180 (2009), 56–67.
56. [56] Group, F.-N.B.W. BEST (Biomarkers, EndpointS, and other Tools) resource. 2016, Food and Drug Administration/National Institutes of Health.
57. [57] Biomarker Development Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69 (2001), 89–95.
58. [58] Lee, J.W., Devanarayan, V., Barrett, Y.C., Weiner, R., Allinson, J., Fountain, S., et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 23 (2006), 312–328.
59. [59] Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimers Dement 8 (2012), 1–72.
60. [60] The Gerontological Society of American Workgroup on Cognitive Impairment Detection: report and recommendations, 2015.
61. [61] Lundquist, T.S., Ready, R.E., Screening for Alzheimer's disease: inspiration and ideas from breast cancer strategies. J Appl Gerontol 34 (2015), 317–328.
62. [62] Mattsson, N., Carrillo, M.C., Dean, R.A., Devous, M.D., Nikolcheva, T., Pesini, P., et al. Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimers Dement (Amst) 1 (2015), 412–419.
63. [63] Quintard, H., Leduc, S., Ferrari, P., Petit, I., Ichai, C., et al. Early and persistent high level of PS 100β is associated with increased poor neurological outcome in patients with SAH: is there a PS 100β threshold for SAH prognosis?. Crit Care, 20, 2016, 33.
64. [64] Winterhoff, B., Fryer, L., Hammond, E., Giri, S., Mondal, S., Roy, D., et al. PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples. Eur J Cancer 51 (2015), 879–892.
65. [65] Clemons, M.J., Cochrane, B., Pond, G.R., Califaretti, N., Chia, S.K.L., Dent, R.A., et al. Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study. Breast Cancer Res Treat 146 (2014), 153–162.
66. [66] Winter, M.C., Wilson, C., Syddall, S.P., Cross, S.S., Evans, A., Ingram, C.E., et al. Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer—a randomized biomarker pilot study. Clin Cancer Res 19 (2013), 2755–2765.
67. [67] Cohen, A.F., Burggraaf, J., VanGerven, J.M.A., Moerland, M., Groeneveld, G.J., The use of biomarkers in human pharmacology (Phase I) studies. Annu Rev Pharmacol Toxicol 55 (2015), 55–74.
68. [68] Hampel, H., O'Bryant, B.S., Castrillo, J.I., Ritchie, C., Rojkova, K., Benda, N., et al. Precision medicine: the golden gate for detection, treatment and prevention of Alzheimer's disease. J Prev Alzheimers Dis, 2016 in press.